Enzalutamide and olaparib synergistically suppress castration-resistant prostate cancer progression by promoting apoptosis through inhibiting nonhomologous end joining pathway

Recent studies revealed the relationship among homologous recombination repair (HRR), androgen receptor (AR), and poly(adenosine diphosphate-ribose) polymerase (PARP); however, the synergy between anti-androgen enzalutamide (ENZ) and PARP inhibitor olaparib (OLA) remains unclear. Here, we showed tha...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Hui-Yu Dong, Pan Zang, Mei-Ling Bao, Tian-Ren Zhou, Chen-Bo Ni, Lei Ding, Xu-Song Zhao, Jie Li, Chao Liang
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Wolters Kluwer Medknow Publications 2023-01-01
Serie:	Asian Journal of Andrology
Ämnen:	apoptosis; enzalutamide; nonhomologous end joining; olaparib; prostate cancer
Länkar:	http://www.ajandrology.com/article.asp?issn=1008-682X;year=2023;volume=25;issue=6;spage=687;epage=694;aulast=
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!